Added to YB: 2025-11-05
Pitch date: 2025-10-31
PALI [bullish]
Palisade Bio, Inc.
-2.51%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Market Cap
$275.3M
Pitch Price
$1.99
Price Target
7.00 (+261%)
Dividend
N/A
EV/EBITDA
-22.53
P/E
-0.58
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The $2 Stock Redefining a Forgotten Mechanism (And Turning It Into Pharma’s Next Big Target
PALI: Gut-targeted PDE4 inhibitor for IBD showing 100% clinical response, 40% remission in 7 days vs months for competitors. $7 price target on potential M&A. New VP from Arena/Abivax (both multi-billion exits). Phase 1b FSCD data coming, IND filing 2025. Risks: small sample size, $6M cash vs $10M burn, early stage.
Read full article (7 min)